How much funding has VectivBio raised?

VectivBio has raised $145.0M in total funding, most recently a Venture Round.

Who are VectivBio's investors?

VectivBio's investors include Ironwood Pharmaceuticals, CTI Life Sciences Fund, Novo Holdings A/S, Sofinnova Partners, Surveyor Capital, Cormorant Asset Management.

Where is VectivBio headquartered?

VectivBio is headquartered in Basel, Switzerland.

What industry is VectivBio in?

VectivBio operates in Biotech, Healthcare.

VectivBio

Acquired

Basel, Switzerland · Founded 2019 · $145.0M raised

Biotech

Healthcare

Headquarters: Basel
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: vectivbio.com
Total Funding: $145.0M
Last Round: $110.0M Venture RoundJan 2023
Rounds: 3

About

VectivBio was a clinical-stage biotechnology company headquartered in Basel, Switzerland, focused on the discovery and development of treatments for severe rare gastrointestinal diseases. Its lead candidate, apraglutide, is an investigational GLP-2 analog designed for short bowel syndrome with intestinal failure. VectivBio listed on NASDAQ in April 2021 and was acquired by Ironwood Pharmaceuticals in June 2023 for approximately $1 billion.

Summary

VectivBio is a Biotech company based in Basel, Switzerland, founded in 2019. It has raised $145.0M in total across 3 rounds, most recently a $110.0M Venture Round round in Jan 2023. Investors include Ironwood Pharmaceuticals, CTI Life Sciences Fund and Novo Holdings A/S.